Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag LEQEMBI®, a new at-home Alzheimer’s drug, named a 2025 TIME Best Invention, treats early stages of the disease with a quick self-injection.

flag LEQEMBI® IQLIK™ (lecanemab-irmb), a subcutaneous autoinjector for early Alzheimer’s disease, has been named a 2025 TIME Best Invention in medical and healthcare. flag Developed by Eisai and Biogen, it’s the first anti-amyloid therapy approved for at-home use, allowing patients with mild cognitive impairment or mild dementia to self-administer treatment after an initial clinic phase. flag Approved in the U.S. in August 2025 and launched October 6, it delivers a dose in about 15 seconds, reducing need for IV infusions and easing healthcare system strain. flag The drug is approved in 50 countries, with more reviews pending. flag It carries a warning for amyloid-related imaging abnormalities (ARIA), which can be serious or fatal, particularly in ApoE ε4 carriers. flag Testing for the gene is advised but not required.

6 Articles